Medistim ASA (0OCD) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

A very good morning from sunny Oslo and welcome to Medistim's presentation of our first quarter twenty twenty six financial results. My name is Karik Rokstra and together with CFO, Thomas Jakobsen, we will together take you through the results. Before getting into the highlights, we like to start this presentation just reminding ourselves on Medistim's track record And also just highlighting that our growth over the past ten years in sales has been close to 11%. And on our EBIT, we have been growing close to 15% over the past ten years in a CAGR way. So that's a reminder of our promise to continue to deliver profitable growth. Let's now dive into the first quarter. So I'm very happy to being able to present another record sales quarter from Medistim. So for the first time, we are exceeding million in revenues. That means 11.1 growth in NOK. We can see that we have some negative currency effects here. So if we adjust for this, we will see that the currency neutral sales development is actually up at 18.5%. And further looking at sales of our own products, which is of course the strategic product portfolio and the most important part of our business, we see that this is up a solid 28.8%. All regions are contributing to this result. Americas is up 30.9% currency neutral this quarter. EMEA up 11.5% and Asia Pacific have a tremendous 57.5% growth. We're also noting that our third party products is down by 30.2% and we will remember that the beginning of last year was very, very strong due to sales to new hospitals in Norway and we couldn't expect that to be repeated in this quarter. When we look at the EBIT at 57,100,000 that is also a very, very strong operating result. It's actually the second best operating result ever, just beaten by the same quarter last year. And if...